Innovative Medicines Initiative

from Wikipedia, the free encyclopedia
The following important information is missing from this article or section:
Almost everything is missing here
Help Wikipedia by researching and pasting it .

Innovative Medicines Initiative (IMI) is an initiative to increase the competitiveness of pharmaceutical research institutions in the European Union. IMI is a public-private partnership between the European Commission and EFPIA , the European Federation of Pharmaceutical Industries and Associations (German: European Union of Pharmaceutical Industries and Associations). IMI is part of the 7th Research Framework Program .

Currently funded projects include:

- EMTRAIN: European Medicines Research Training Network, German: European Medicine-Research-Training-Network

- Eu2P: European program in Pharmacovigilance and Pharmacoepidemiology, German: European program on side effects ( pharmacovigilance ) and effects of drugs in the population ( pharmacoepidemiology )

- Pharmatrain: Pharmaceutical Medicine Training Program, German: Pharmaceutical Medicine Training Program

- SafeSciMET: European Modular Education and Training Program in Safety Sciences for Medicines, German: European modular education and training program in safety sciences for medicine

Web links